(19)
(11) EP 4 770 641 A1

(12)

(43) Date of publication:
08.07.2026 Bulletin 2026/28

(21) Application number: 24776356.8

(22) Date of filing: 30.08.2024
(51) International Patent Classification (IPC): 
A61K 31/4025(2006.01)
A61K 31/7115(2006.01)
A61K 39/00(2006.01)
A61P 35/00(2006.01)
 A61K 31/407(2006.01)
A61K 33/243(2019.01)
A61K 45/06(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 31/407; A61K 31/4025; A61K 45/06; A61P 35/00; A61K 33/243; A61K 31/7115; C07K 16/2818; A61K 2039/507; A61K 2239/31; A61K 2239/38
 
C-Sets:
  1. A61K 31/7115, A61K 2300/00;
  2. A61K 31/407, A61K 2300/00;
  3. A61K 31/4025, A61K 2300/00;
  4. A61K 33/243, A61K 2300/00;
(86) International application number:
PCT/IB2024/058465
(87) International publication number:
WO 2025/046537 (06.03.2025 Gazette 2025/10)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
GE KH MA MD TN

(30) Priority: 31.08.2023 WO PCT/IB2023/058633

(71) Applicants:
  • Taiho Pharmaceutical Co., Ltd.
    Chiyoda-ku Tokyo 101-8444 (JP)
  • MSD International GmbH
    6006 Luzern (CH)

(72) Inventor:
  • HIRAYAMA, Naoki
    Chiyoda-ku, Tokyo 101-8444 (JP)

(74) Representative: Bradley, Josephine Mary et al
Kilburn & Strode LLP Lacon London 84 Theobalds Road
London WC1X 8NL
London WC1X 8NL (GB)

   


(54) METHODS OF TREATING CANCER USING FUTIBATINIB, PEMBROLIZUMAB AND AT LEAST ONE ADDITIONAL CHEMOTHERAPEUTIC AGENT